Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study

Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study

Abstract Background Inhaled nitric oxide (iNO) is used as rescue therapy in patients with refractory hypoxemia due to severe COVID-19 acute respiratory distress syndrome (ARDS) despite the recommendation against the use of this treatment. To date, the effect of iNO on the clinical outcomes of critic...

Full description

Bibliographic Details
Main Authors: Khalid Al Sulaiman, Ghazwa B. Korayem, Ali F. Altebainawi, Shmeylan Al Harbi, Abdulrahman Alissa, Abdullah Alharthi, Raed Kensara, Amjaad Alfahed, Ramesh Vishwakarma, Hussain Al Haji, Naif Almohaimid, Omar Al Zumai, Fahad Alrubayan, Abdulmajid Asiri, Nasser Alkahtani, Abdulaziz Alolayan, Samiah Alsohimi, Nawal Melibari, Alaa Almagthali, Seba Aljahdali, Abeer A. Alenazi, Alawi S. Alsaeedi, Ghassan Al Ghamdi, Omar Al Faris, Joud Alqahtani, Jalal Al Qahtani, Khalid A. Alshammari, Khalil I. Alshammari, Ohoud Aljuhani
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Critical Care
Subjects:
COVID-19
SARS-CoV-2
Acute respiratory distress syndrome (ARDS)
Inhaled nitric oxide
iNO
Oxygenation parameter
Online Access:https://doi.org/10.1186/s13054-022-04158-y

Internet

https://doi.org/10.1186/s13054-022-04158-y

Similar Items